Affitech's AT001 Enters Clinic, as Delisting Looms
Clinical testing of Affitech A/S' lead antibody, AT001/r84, began this week, just as the company enters its final weeks as a publicly quoted entity and prepares to become a private entity, wholly owned by Russian investors.
Next week, the antibody developer will learn the outcome of a tender process for the remaining 15 percent of its stock that is not already owned by its majority shareholder, Trans Nova Investments Ltd., or an allied entity, Krosalter Enterprises Ltd.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST